Company: DVAX
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001029142-25-000117
Chunk: 208

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 208
---
 2025 and December 31, 2024- - Common stock: $0.001 par value, 278,000 shares authorized at June 30, 2025 and December 31, 2024; 117,230 shares and 125,450 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively117 125 Additional paid-in capital1,474,046 1,504,671 Accumulated other comprehensive income (loss)652 (4,722)Accumulated deficit(980,653)(903,275)Total stockholders’ equity494,162 596,799 Total liabilities and stockholders’ equity$918,449 $986,256 

See accompanying notes.

4

Table of Contents

Dynavax Technologies Corporation 

Condensed Consolidated Statements of Operations 

(In thousands, except per share amounts) 

(Unaudited) 

Three Months Ended June 30,Six Months Ended June 30,2025202420252024Revenues:    Product revenue, net$91,872 $70,188 $156,831 $118,032 Other revenue3,570 3,607 6,775 6,552 Total revenues95,442 73,795 163,606 124,584 Operating expenses:    Cost of sales - product14,035 11,985 27,804 22,952 Research and development16,619 14,950 35,996 28,478 Selling, general and administrative50,359 41,662 98,037 85,727 Bad debt expense— — 10,970 — Total operating expenses81,013 68,597 172,807 137,157 Income (loss) from operations14,429 5,198 (9,201)(12,573)Other income (expense):    Interest income6,798 9,201 14,537 18,668 Interest expense(1,641)(1,698)(3,333)(3,393)Sublease income2,226 2,205 4,452 603 Loss on debt extinguishment— — (82,095)— Other (loss) income(596)— (1,019)103 Net income (loss) before income taxes21,216 14,906